Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss

  • 📰 wjxt4
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

Business ニュース

日本 最新ニュース,日本 見出し

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations.

LIVE: Secretary of State Brad Raffensperger gives update on early voting after Georgians break 3 million mark

Read full article: LIVE: Secretary of State Brad Raffensperger gives update on early voting after Georgians break 3 million markEstranged couple accused in murder-for-hire plot appears in court for pre-trial hearingKeep your drink cold longer with these tumblers. See more Insider Deals here.Looking to save on items for your home, road trip and wardrobe? We've got the latest Insider Deals to share!FILE - This April 26, 2017 file photo shows the Eli Lilly & Co.

Leerink Partners analyst David Risinger said separately that although Lilly’s results were disappointing, he is keeping his “outperform” rating on the stock. He noted that Lilly “is just getting started in commercializing obesity products globally.”

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 246. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し